Celularity and GX Acquisition Corp. announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity.
Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.